NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SpeeDx

SpeeDx

Private
SydneyHealthcare & Life Scienceshttps://www.speedxpcr.com/

Last Round

Series C

Feb 28, 2023

Total Funding Raised

$52.01M

Company Overview

SpeeDx is a molecular diagnostics company that develops innovative multiplex systems for clinical diagnostics utilizing real-time polymerase chain reaction technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

molecular diagnosticsqPCRmultiplex PCRinfectious disease testingantibiotic resistance testingdiagnostic assaysprecision medicineSTI testingrespiratory viral panelsmolecular testingpathology diagnosticsdiagnostic kitslab diagnosticsclinical diagnosticsbiotech reagents

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SpeeDx Comparables

Compare SpeeDx with similar companies based on industry and business-model similarity.

SpeeDx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ChromaCode
80%
Seegene Inc.
79%
R-Biopharm AG
78%

SpeeDx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 28, 2023
GrantJul 16, 2021
GrantMay 10, 2021
GrantSep 3, 2020
Series BFeb 11, 2020
Series A
Aug 5, 2019

Key People

Founding team and executive leadership

Alison V. Todd AM FTSE

Chief Scientific Officer Founder

Founding Team

Jeremy Stackawitz

Chief Executive Officer

Executive Team

Elisa M.

Chief Technology Officer

Executive Team

SpeeDx Investors

Notable investors and investment history

SpeeDx investors
InvestorRounds
CARB-XGrant
Platinum Asset ManagementSeries C
NSW Medical Device FundGrant
Northpond VenturesSeries C, Series A, Series B
TattarangSeries C
Northpond VenturesSeries C, Series A, Series B
Australian Government Department of Industry, Science and ResourcesGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 5, 2019

    $15M round led by Northpond Ventures.

  • Sep 4, 2017

    $2M raised from NSW Medical Device Fund.

SpeeDx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SpeeDx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SpeeDx's valuation, stock price, and market status.

Firmographic Details

HeadquartersSydney
Employee Range85
Year Founded2009
Last FundingFeb 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.